Science
-
Research updates, November 3
Multiple COVID-19 precautions during the Tokyo Olympic and Paralympic Games were effective in minimizing SARS-CoV-2 transmission, according to a new study in Eurosurveillance. Using retrospective epidemiological data, Japanese researchers found that spread was very low during the games, as most cases occurred during arrival or mandatory quarantines before the games.
-
Novel drug bezisterim plans for further study in Long COVID. Here’s how the phase 2 trial came together.
Novel anti-inflammatory drug shows early promise in treating Long COVID cognitive symptoms, fatigue, PEM. The study looked at multiple endpoints and consulted with people living with the disease.
-
Research updates, October 27
Low-dose prednisolone may temporarily reduce some “symptom severity” of Long COVID, according to a new study in eClinicalMedicine. German researchers evaluated the drug, a corticosteroid that reduces inflammation and is used to treat a broad range of conditions, alongside some B vitamins, in the phase 3 clinical trial.
-
The real story behind the “October slide”
Changing seasons affect many people with Long COVID, myalgic encephalomyelitis, and other chronic illnesses, but not all in the same way. Research has a long way to go before it can explain the phenomenon.
-
Research updates, October 20
A large Long COVID review found mechanisms of “accelerated biological aging” in young adults. The review was published in Ageing Research Reviews and synthesized 110 mechanistic and epidemiological Long COVID studies on adults ages 25–55.
-
Research updates, October 13
A new study found COVID-19 was linked to a significant increase in dementia in older people with type 2 diabetes. The retrospective study published in Frontiers in Aging Neuroscience included a cohort of nearly half a million people with documented SARS-C0V-2 infections.
-
Biological pathways and mechanistic trials centered at new Long COVID conference in Amsterdam
Researchers, clinicians, and advocates gathered for the inaugural conference of the International Society for Long COVID and Post-Acute Infection Syndromes in the Netherlands in late August. The four-day event featured hundreds of presentations and posters about trials and disease mechanisms.
-
Research updates, October 6
As many as 2.3 million new cases of cancer were triggered by viral infections worldwide in 2024, according to new research in The Lancet Oncology. French researchers analyzed a large database of cancer incidence from 2024, looking at specific diagnoses that were attributable to infections.
-
Research updates, September 29
A small clinical trial found Remdesivir was safe for people with Long COVID and that some exploratory results warrant a larger trial. The U.K. trial, which included 73 participants who took a five day course of the intravenous antiviral COVID-19 drug, was published in Oxford Open Immunology.
-
People with Long COVID demand pause of McMaster University clinical trial
The trial, run by researchers at McMaster University in Canada, is testing the Lightning Process, a pseudoscientific mind-body program that outside experts have heavily criticized.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance